Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 4/20 | 0.87 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.87 |
| ▸ | CA12 | O43570 | 2/20 | 0.87 |
| ▸ | CA2 | P00918 | 2/20 | 0.87 |
| ▸ | CA4 | P22748 | 2/20 | 0.87 |
| ▸ | CA7 | P43166 | 2/20 | 0.87 |
| ▸ | ACHE | P22303 | 1/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.76 |
| ▸ | GAA | P10253 | 4/20 | 0.76 |
| ▸ | POLB | P06746 | 3/20 | 0.76 |
| ▸ | APEX1 | P27695 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.75 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.75 |
| ▸ | KDM1A | O60341 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30217565 | 1.00 | P4HB (0.87) | P4HBAKR1B1CA12CA2CA4 | |
| SCHEMBL27193647 | 1.00 | P4HB (0.87) | P4HBAKR1B1CA12CA2CA4 | |
| SCHEMBL9993788 | 1.00 | P4HB (0.87) | P4HBAKR1B1CA12CA2CA4 | |
| SCHEMBL4391457 | 1.00 | P4HB (0.87) | P4HBAKR1B1CA12CA2CA4 | |
| SCHEMBL31173775 | 1.00 | P4HB (0.87) | P4HBAKR1B1CA12CA2CA4 | |
| SCHEMBL30456667 | 0.95 | P4HB (0.79) | P4HBAKR1B1CA12CA2CA4 | |
| SCHEMBL9993267 | 0.95 | P4HB (0.79) | P4HBAKR1B1CA12CA2CA4 | |
| SCHEMBL30217549 | 0.95 | P4HB (0.79) | P4HBAKR1B1CA12CA2CA4 | |
| SCHEMBL30637576 | 0.95 | P4HB (0.79) | P4HBAKR1B1CA12CA2CA4 | |
| SCHEMBL31720497 | 0.95 | P4HB (0.79) | P4HBAKR1B1CA12CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119055666-A | Application of active compound derived from epimedium total flavone in inhibiting androgen receptor | 山西医科大学 | 2024-12-03 | — | — | CN | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| CN-114031656-B | Medicine for treating urinary system lithiasis related diseases and preparation method thereof | 张弘 | 2025-05-27 | — | — | CN | disclosed |
| CN-119818577-A | Traditional Chinese medicine composition with vaginal tightening effect and preparation method and application thereof | 广东格美健康科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119055666-A | Application of active compound derived from epimedium total flavone in inhibiting androgen receptor | 山西医科大学 | 2024-12-03 | — | — | CN | disclosed |
| CN-119055666-A | Application of active compound derived from epimedium total flavone in inhibiting androgen receptor | 山西医科大学 | 2024-12-03 | — | — | CN | disclosed |
| CN-117582464-A | Extraction method and application of active ingredients for treating cerebral infarction in Va drug Nie Liang administration | 云南省中医医院(云南中医药大学第一附属医院) | 2024-02-23 | — | — | CN | disclosed |
| CN-115212252-A | Application of Va drug Nierone in preparation of drugs for treating cerebral infarction | 云南省中医医院(云南中医药大学第一附属医院) | 2022-10-21 | — | — | CN | disclosed |
| WO-2022151978-A1 | DRUG FOR TREATING UROLITHIASIS-RELATED DISEASE, AND PREPARATION METHOD THEREFOR | 张弘 | 2022-07-21 | — | — | WO | disclosed |
| CN-114031656-A | Medicine for treating urinary calculus related diseases and preparation method thereof | 张弘 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | P4HB 1151/4885AKR1B1 2311/4885CA12 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.